Daniel M Paulson

Summary

Affiliation: Sanofi-Aventis Deutschland GmbH

Publications

  1. ncbi request reprint Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction--a 21-day treatment-randomized clinical trial
    Daniel M Paulson
    VA Medical Center, Richmond, USA
    J Pain 6:184-92. 2005

Detail Information

Publications1

  1. ncbi request reprint Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction--a 21-day treatment-randomized clinical trial
    Daniel M Paulson
    VA Medical Center, Richmond, USA
    J Pain 6:184-92. 2005
    ..Alvimopan, a novel peripheral opioid mu-receptor antagonist, has demonstrated significant efficacy for the management of opioid-induced bowel dysfunction without compromise of centrally mediated opioid-induced analgesia...